Intervet vaccination administration approved

Intervet/Schering-Plough Animal Health has been granted safety and efficacy claim approvals for the transdermal administration of three vaccines, it has been reported.

The three vaccines include the modified-live virus (MLV) strains of Bovine Virus Diarrhoea (BVD) Type 1 and Type 2, the avirulent-live culture strains of Pasteurella multocida and Mannheimia haemolytica and Infectious Bovine Rhinotracheitis (IBR).

This will allow dairy and beef producers to have another option for needle-free vaccine administration, according to a report by Cattle Network.

People looking for animal health jobs may be interested in the new transdermal technique, as it reduces stress for the animal while improving immune response, the company’s manager for Veterinary Technical Services Dr Scott Nordstrom said.

“Transdermal administration, like intranasal administration, offers a highly efficacious and safe, needle-free option for vaccine delivery,” he commented.

Dr Nordstrom added that using both these forms of non-invasive vaccine administration “provide a proven immunologic advantage”.

The Centre for Veterinary Biologics with the US Department of Agriculture granted the claim approvals.

Intervet recently offered a poultry vaccination scheme.